21CTP.LEUK01:Asciminib,Dasatinib,Prednisone,and Blinatumomab Newly Diagnosed Phila Chromo ALL - Clinical Trial
Who Can Participate in the Study?
Age Group
Adults
Study Details
Full Title
A Phase II Trial of Asciminib, Dasatinib, Prednisone, and Blinatumomab for Participants with Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia
Principal Investigator
Harry P. Erba, MD, PhD
Hematologic Oncologist
Protocol Number
IRB:
PRO00118445
NCT:
NCT06773936
Phase
Phase II
ClinicalTrials.gov
View on ClinicalTrials.gov
Enrollment Status
Open for Enrollment